Skip to main content
. 2020 Apr 20;27(10):505–515. doi: 10.1038/s41434-020-0146-8

Fig. 3. Perinatal administration of AAV8-Klf15 slightly increases survival in Smn2B/− SMA mice.

Fig. 3

Postnatal day (P) 0 Smn2B/− SMA mice and control littermates were either untreated or received a single facial vein intravenous injection of AAV8-GFP or AAV8-Klf15 (2E10 vg/pup). a Survival curves of untreated (n = 15), AAV8-GFP-treated (n = 18) and AAV8-Klf15-treated (n = 11) Smn2B/− mice. Data are Kaplan–Meier survival curves, log-rank Mantel–Cox test, **p = 0.0021 (untreated vs AAV8-GFP), ****p < 0.0001 (untreated vs AAV8-Klf15), ***p = 0.0008 (AAV8-GFP vs AAV8-Klf15). b Daily weights of untreated (n = 18), AAV8-GFP-treated (n = 18) and AAV8-Klf15-treated (n = 11) Smn2B/− mice. Data are mean ± SEM, two-way ANOVA, */^/#p < 0.05, **/^^p < 0.01, ^^^p < 0.001, ^^^^p < 0.0001. c Daily weights of untreated (n = 11), AAV8-GFP-treated (n = 9), and AAV8-Klf15-treated (n = 16) Smn2B/+ mice. Data are mean ± SEM, two-way ANOVA, ns = not significant.